Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 4Non Small Cell Lung Cancer Metastatic 3Neoplasms 2Recurrence 1Neoplasm Metastasis 1Neoadjuvant Non-Small Cell Lung Cancer 1Lymphoma, Large-Cell, Anaplastic 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

lorlatinib 3osimertinib 2pembrolizumab 1Radiosurgery 1Fecal Microbiota Transplantation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Non Small Cell Lung Cancer Metastatic × lorlatinib × Clear all
NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Active not recruiting
54 enrolled
Thoracic

Non Small Cell Lung Cancer Metastatic

NCT04111705 2025-04-01

ORAKLE

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Completed
23 enrolled
Thoracic

Non Small Cell Lung Cancer Metastatic

NCT06378892 2024-04-23

ALK-PPL

Centro di Riferimento Oncologico - Aviano

Phase 2 Recruiting
45 enrolled
Thoracic

Non Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡